Hypophosphatemia after treatment with parenteral iron: case report
DOI:
https://doi.org/10.6016/ZdravVestn.3165Keywords:
adverse effect, ferric carboxymaltose, iron deficiency anaemia, iron supplementation, phosphate deficiencyAbstract
Iron deficiency anaemia is the most common anaemia worldwide, affecting mainly children, women of childbearing potential and pregnant women, and is increasingly present in chronic patients and the elderly population. The basic method of replacement is oral preparations, which often cause side effects, but sometimes this type of replacement is insufficient, due to lack of intake, i.e., gastrointestinal malabsorption or persistent bleeding. Another way is the parenteral replacement, in recent years most commonly with ferric carboxymaltose. This medicine is safe, and its side effects are relatively rare and mostly mild to moderate. Of the metabolic disorders, the most common is hypophosphatemia, the incidence of which has not yet been clearly defined in the literature but is not negligible. In most cases, it is asymptomatic and transient, but can also be severe and long-lasting. The paper describes the case of a young patient with severe symptomatic hypophosphatemia of 0.24 mmol/L after ferric carboxymaltose applications. We add a brief review of the literature and an algorithm of clinical action.
Downloads
References
1. Miller JL. Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med. 2013;3(7):1-13.
DOI: 10.1101/cshperspect.a011866
PMID: 23613366
2. Cappellini MD, Musallam KM, Taher AT. Iron deficiency anaemia revisited. J Intern Med. 2020;287(2):153-70.
DOI: 10.1111/joim.13004
PMID: 31665543
3. Roškar Z. Sideropenična anemija v ambulanti družinskega zdravnika. In: Kupnik D. III. spomladanska šola družinske medicine v Mariboru: hematološke bolezni. 2018 May 22; Maribor, Slovenija. V Mariboru: Zdravstveni dom dr. Adolfa Drolca Maribor; 2018.
4. Cvejić Vidali G, Zver S. Analiza bolnikov z anemijo zaradi pomanjkanja železa v hematološki ambulanti. Zdrav Vestn. 2018;87(5–6):223-36.
DOI: 10.6016/ZdravVestn.2523
5. Rognoni C, Venturini S, Meregaglia M, Marmifero M, Tarricone R. Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. Clin Drug Investig. 2016;36(3):177-94.
DOI: 10.1007/s40261-015-0361-z
PMID: 26692005
6. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Mangione Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Postpartum Anemia. Obstet Gynecol. 2008;110(2):267-78.
DOI: 10.1097/01.AOG.0000275286.03283.18
PMID: 17666600
7. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69(6):739-56.
DOI: 10.2165/00003495-200969060-00007
PMID: 19405553
8. Moore RA, Gaskell H, Rose P, Allan J. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 2011;11(1):4.
DOI: 10.1186/1471-2326-11-4
PMID: 21942989
9. Gómez Rodríguez S, Castro Ramos JC, Abreu Padín C, Gómez Peralta F. Intravenous iron induced severe hypophophatemia in a gastric bypass patient. Endocrinol Diabetes Nutr (Engl Ed). 2019;66(5):340-2.
DOI: 10.1016/j.endien.2019.05.003
PMID: 30658902
10. Fang W, McMahon LP, Bloom S, Garg M. Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose. JGH Open. 2019;3(5):438-40.
DOI: 10.1002/jgh3.12150
PMID: 31633052
11. Gaasbeek A, Meinders AE. Hypophosphatemia: an update on its etiology and treatment. Am J Med. 2005;118(10):1094-101.
DOI: 10.1016/j.amjmed.2005.02.014
PMID: 16194637
12. Yu AS, Stubbs JR. Hypophosphatemia: Clinical manifestations of phosphate depletion. UpToDate. [cited 2021 Mar 3]. Available from: https://www.uptodate.com/contents/hypophosphatemia-clinical-manifestations-of-phosphate-depletion.
13. Gubenšek J. Motnje v presnovi fosfatov. In: Košnik M, Štajer D. Interna medicina. Ljubljana: Medicinska fakulteta; 2018. pp. 99-101.
14. Czaya B, Fail C. The Role of Fibroblast Growth Factor 23 in Inflammation and Anaemia. Int J Mol Sci. 2019;20(17):4195.
DOI: 10.3390/ijms20174195
PMID: 31461904
15. Reinert RB, Bixby D, Koenig RJ. Fibroblast Growth Factor 23-Induced Hypophosphatemia in Acute Leukemia. J Endocr Soc. 2018;2(5):437-43.
DOI: 10.1210/js.2018-00010
PMID: 29696242
16. Klein K, Asaad S, Econs M, Rubin JE. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep. 2018;2018.
DOI: 10.1136/bcr-2017-222851
PMID: 29298794
17. Emrich IE, Lizzi F, Siegel JD, Seiler-Mussler S, Ukena C, Kaddu-Mulindwa D, et al. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study. BMC Med. 2020;18(1):178.
DOI: 10.1186/s12916-020-01643-5
PMID: 32654663
18. Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al.; FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846-853.e1.
DOI: 10.1053/j.gastro.2011.06.005
PMID: 21699794
19. Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015;2015:468675.
DOI: 10.1155/2015/468675
PMID: 26000018
20. Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women—PREFER a randomized, placebo-controlled study. PLoS One. 2014;9(4):e94217.
DOI: 10.1371/journal.pone.0094217
PMID: 24751822
21. Barish CF, Koch T, Butcher A, Morris D, Bregman DB. Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anaemia: Two Randomized, Controlled Trials. Anemia. 2012;2012:172104.
DOI: 10.1155/2012/172104
PMID: 22997572
22. Bager P, Hvas CL, Dahlerup JF. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol. 2017;83(5):1118-25.
DOI: 10.1111/bcp.13189
PMID: 27859495
23. Amrein K, Scherkl M, Hoffmann M, Neuwersch-Sommeregger S, Köstenberger M, Tmava Berisha A, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr. 2020;74(11):1498-513.
DOI: 10.1038/s41430-020-0558-y
PMID: 31959942
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
